Do You Zoster Vaccinate? (6.19.2026)
Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026.
Read Article
EULAR 2026: Updated Recommendations for Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases
The 2026 EULAR vaccination recommendations, presented by Victoria Furer, were developed by a multinational 25-member task force that include rheumatologists, an https://t.co/AFnsmEYj41
Dr. John Cush @RheumNow( View Tweet )
Is there a path to precision medicine in #RA? Theres a substantial unmet need. Immunoengineering is possible thru nanotechnological delivery vectors, cellular therapeutics, & biomaterial scaffolds, with compelling preclinical and early clinical support. https://t.co/gL56EOlt7p https://t.co/IFSHOM8g7w
Dr. John Cush @RheumNow( View Tweet )
Single center study of 102 pts starting JAK inhibitor (72% >50yrs; 77% RA) shows only 27.5% received at least one RZV vaccination dose (Shingrix) & only 3 recv RZV within 30 daysof a JAK inhibitor. ????? (I vaccinate everyone going on a JAKi w/ Shingrix - don't you?) https://t.co/7HUqGGBeJ8
Dr. John Cush @RheumNow( View Tweet )
MTX: SC vs Oral? Metanalysis of 9 RCTs, 974 RA pts. Compared w/ oral, SC MTX signif. incr odds of ACR20 (RR=1.15), ACR50 (RR=1.14) & reduced GI adverse events (RR=0.58), diarrhea (RR=0.42): BUT no difference in ACR70, DAS28-ESR, bioavailability AUC, or other AE https://t.co/54xVnerRuS
Dr. John Cush @RheumNow( View Tweet )
CAR-T Cell Therapies at EULAR 2026
EurekAlert!
In an oral abstract presentation on Wednesday 3rd June, Fredrik Albach presented results for mivocabtagene autoleucel – an autologous, fully human CD19-directed CAR-T cell therapy – from Phase 1 of the prospective, open-label COMPARE trial in six patients with anti-
Read Article
EULAR26 Insights into Gout and Obesity
EurekAlert!
New EULAR 2026 data show continued treat-to-target ULT beats a discontinuation strategy for maintaining gout remission (79.2% vs. 62.9% flare-free), though many who stopped still stayed flare-free. A companion study links gout and rheumatoid arthritis to distinct, adverse body fat patterns tied
Read Article
Increased VTE Risk with Baricitinib
The RA-BRIDGE and RA-BRANCH studies were presented as a late-breaking abstract at EULAR 2026 (LB0009). This was the pooled results from two large FDA post-marketing commitment safety trials — RA-BRIDGE (global) and RA-BRANCH (US-only) — https://t.co/5cQ829x77u
Dr. John Cush @RheumNow( View Tweet )
EULAR 2026: Updated Recommendations for Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases
This update includes new pandemic era evidence, recombinant zoster vaccine data, and new perspectives on vaccination in patients taking novel immunosuppressants. Five overarching principles and 10 vaccine recommendations follow.
Read Article
Late-Breaking Studies at EULAR 2026
MedPage Today
Late-breaking abstracts presented at the European Alliance of Associations for Rheumatology's (EULAR) annual meeting, held here last week, addressed a wide range of clinical
Read Article
20% sample of elder RA Medicare pts (2009-2022) on TNFi who either stopped or tapered TNFi found 38% sustained de-escalation, while 62% re-escalated within a medianof 164. Re-escalation was more likely in Blacks, Hispanic/other, with a lower comorbidity burden. https://t.co/rEB3VdOii2
Dr. John Cush @RheumNow( View Tweet )
From BiTE to TriTE: Progress of T-cell Engagers in RMDs
At EULAR 2026 in London, T-cell engagers drew attention as a strategy to achieve deep B-cell depletion and drug-free remission in refractory RMDs. BiTEs offer off-the-shelf availability, reversible toxicity from short https://t.co/o8Tn77aYRg
Dr. John Cush @RheumNow( View Tweet )
Danish hospital 574 newly diagnosed RA pt, 75% recv glucocorticoids (GC) in 1st yr (55% 1st visit) -- mean dose was 9.3 mg/day, with 46% recv oral tablets & 47% IA steriods injections. 20% had an infection in 1st Yr (RR 1.13; 0.77 to 1.67). Doses declined after 1st visit, but not https://t.co/JcerD61m0t
Dr. John Cush @RheumNow( View Tweet )
MTX: SC vs Oral? Metanalysis of 9 RCTs, 974 RA pts. Compared w/ oral, SC MTX signif. incr odds of ACR20 (RR=1.15), ACR50 (RR=1.14) & reduced GI adverse events (RR=0.58), diarrhea (RR=0.42): BUT no difference in ACR70, DAS28-ESR, bioavailability AUC, or other AE https://t.co/tQeQz7H7do
Dr. John Cush @RheumNow( View Tweet )
True or False: RA-associated ILD is considered one of the few RA outcomes that has not improved in the biologic era. See if you got it right in this week's RheumIQ quiz at https://t.co/Fnzn4UPu0n https://t.co/L7lAA6lwMp
Dr. John Cush @RheumNow( View Tweet )
Increased VTE Risk with Baricitinib
The RA-BRIDGE and RA-BRANCH studies were presented as a late-breaking abstract at EULAR 2026. This was the pooled results from two large FDA post-marketing commitment safety trials — RA-BRIDGE (global) and RA-BRANCH (US-only) — comparing baricitinib at 2 mg and 4 mg daily against TNF
Read Article
Single center study of 102 pts starting JAK inhibitor (72% >50yrs; 77% RA) shows only 27.5% received at least one RZV vaccination dose (Shingrix) & only 3 recv RZV within 30 daysof a JAK inhibitor. ????? (I vaccinate everyone going on a JAKi w/ Shingrix - don't you?) https://t.co/j2jrBIiuOo
Dr. John Cush @RheumNow( View Tweet )
From BiTE to TriTE: Progress of T-cell Engagers in RMDs
The EULAR 2026 Congress in London showcased growing interest in T-cell engagers as a novel strategy to achieve deep B-cell depletion and drug-free remission in refractory rheumatic and musculoskeletal diseases (RMDs). Bispecific T-cell engagers (BiTE) aim to overcome limitations of
Read Article
RA-ILD in the Age of Treat-to-Target: Put the Probe on the Chest
RA inflammation may be under control, but RA-associated ILD remains a major challenge. At #EULAR2026, experts highlighted that ILD is one of the few RA outcomes not improving in the biologic era. Three new https://t.co/Qujhl3ktRp
Dr. John Cush @RheumNow( View Tweet )
RA-ILD: Screening risk and genetic susceptibility
Two abstracts presented at EULAR 2026 add important insights into identifying patients at risk for RA-ILD and understanding the genetic mechanisms that may underpin disease development.
https://t.co/IABp8NhUtS https://t.co/j8UHK2GRd7
Dr. John Cush @RheumNow( View Tweet )
EULAR 2026 Rheumatology RoundUp
It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.
Read Article
When Patients with RA Choose Their Treatment, Outcomes Are Better — Here's the Data
Dr. Aurelie Najm discusses abstract OP0204 presented in London at the EULAR 2026 Congress.
https://t.co/hHQFffTXH0 https://t.co/tXv0SnGBz1
Dr. John Cush @RheumNow( View Tweet )
Immune Dimming or Immune Reset in RA: How Far Should We Go?
CD19 CAR T-cell therapy has moved from oncology to autoimmune disease after SLE reports of sustained drug-free remission suggesting an immune reset. This raises whether profound depletion is needed or if milder https://t.co/WONQmhs86j
Dr. John Cush @RheumNow( View Tweet )
NK Cells Without a CAR: AB-101 Is Neither CAR-T nor CAR-NK
Much of the meeting came for the next CAR T readout. AB-101 drew attention for a different reason. It depletes B cells by a completely different route.
Read ArticleTherapeutic Updates
Expert insights on the 2024 ACR Guideline recommendations for lupus nephritis
Sponsored by Aurinia
Two experts in lupus care offer a balanced perspective on applying the updated ACR Guideline recommendations and the clinical nuances of managing lupus nephritis.
Read Post
Recent Blogs
Podcasts
EULAR 2026 RA Topic Panel
RA Topic Podcast compilation
EULAR 2026 Daily Podcast Day 4c
